Prostaglandins in Relation to Carcinomas in Man and Laboratory Animals

  • Alan Bennett
Part of the NATO Advanced Study Institutes Series book series


Various studies have shown that most tumours can produce more prostaglandins (PGs) than the normal tissues in which they arise (see Ref. 1). However, we still know little about which types of PGs and related substances are formed,or about the effects of many prostanoids and lipoxygenase products on tumour growth and spread. Whereas the source of these substances is clear with pure cell lines in culture, whole tumours contain numerous different cell types which can form PGs. In the following account there are brief discussions on PGs and cell growth, endocrine tumours, breast cancer, malignant hypercalcaemia, unwanted effects of cancer therapy, and beneficial effects of PG synthesis inhibitors in mice with tumours.


Breast Cancer Bone Destruction Calcium Ionophore Gastric Mucosal Damage Lipoxygenase Product 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    A. Bennett. Prostaglandins and cancer. In: Practical Applications of Prostaglandins and Their Synthesis Inhibitors. S. M. M. Karim, ed., M.T.P. Press, Lancaster, pp. 149–188 (1979).Google Scholar
  2. 2.
    L. J. De Asua, D. Clingan and P. S. Rudland. Initiation of cell proliferation in cultured mouse fibroblasts by prostaglandin F. Proc. Nat. Acad. Sci., 72: 2724–2728 (1975).PubMedCrossRefGoogle Scholar
  3. 3.
    D. R. Thomas, G. W. Philpott and B. M. Jaffe. Prostaglandin E control of cell replication in vitro. J. Surg. Res., 16: 463–465 (1974).Google Scholar
  4. 4.
    V. Hial, M. C. F. de Mello, Z. Horakova and M. A. Beavan. Antiproliferative activity of anti-inflammatory drugs in two mammalian cell culture lines. J. Pharm. Exp. Ther., 202: 446–454 (1977).Google Scholar
  5. 5.
    J. P. MacManus and J. F. Whitfield. Cyclic AMP, prostaglandins and the control of cell proliferation. Prostaglandins, 6: 475–487 (1974).PubMedGoogle Scholar
  6. 6.
    J. F. Whitfield, R. H. Rixon, J. P. MacManus and S. D. Balk. Calcium, cycli adenosine 3’, 5’-monophosphate, and the control of cell proliferation: a review. In itro, 8: 257–278 (1973).Google Scholar
  7. 7.
    S. Abraham and G. A. Rao. Lipids and lipogenesis in a murine mammary neoplastic system. In: Control Mechanisms in Cancer. W. E.Criss, ed., Raven Press, New York, pp. 363–378 (1976).Google Scholar
  8. 8.
    H. Strausser and J. Humes. Prostaglandin synthesis inhibition: effect on bone changes and sarcoma tumour induction in BALB/c mice. Int. J. Cancer, 15: 724–730 (1975).PubMedCrossRefGoogle Scholar
  9. 9.
    O. J. Plescia, A. H. Smith and K. Grinwich. Subversion of immune system by tumour cells and role of prostaglandins. Proc. Nat. Acad. Sci., 72: 1848–1851 (1975).PubMedCrossRefGoogle Scholar
  10. 10.
    M. Harris, M. V. Jenkins, A. Bennett and M. R. Wills. Prostaglandin production and bone resorption by dental cysts. Nature, 245: 213–215 (1973).PubMedCrossRefGoogle Scholar
  11. 11.
    A. Bennett, I. F. Stamford and W. G. Unger. Prostaglandin E2 and gastric acid secretion in man. J. Physiol., 229: 349–360 (1973).PubMedGoogle Scholar
  12. 12.
    W. G. Unger, I. F. Stamford and A. Bennett. Extraction of prostaglandins from human blood. Nature, 233: 336–337 (1971).PubMedCrossRefGoogle Scholar
  13. 13.
    A. Bennett, A. M. McDonald, J. S. S mpson and I. F. Stamford. Breast cancer, prostaglandins and bone metastases. Lancet, 1: 1218–1220 (1975).PubMedCrossRefGoogle Scholar
  14. 14.
    A. Bennett, E. M. Charlier,A. M. McDonald, J. S. Simpson and I. F. Stamford. Bone destruction by breast tumours. Prostaglandins, 11: 461–463 (1976).Google Scholar
  15. 15.
    A. Bennett, E. M. Charlier, A. M. McDonald, J. S. Simpson, I. F. Stamford and T. Zebro. Prostaglandins and breast cancer. Lancet, 2: 624–626 (1977).PubMedCrossRefGoogle Scholar
  16. 16.
    M. Dowsett, G. C. Easty, T. J. Powles, D. M. Easty and A. M. Neville. 11=49 n breast tumour-induced osteolysis and prostaglandins. Prostaglandins, 11: 447–455 (1976).PubMedGoogle Scholar
  17. 17.
    T. J. Powles, S. A. Clark, D. M. Easty, G. C. Easty and A. M. Neville. The inhibition by aspirin and indomethacin of osteolytic tumour deposits and hypercalcaemia in rats with Walker tumour, and its possible application to breast cancer. Br. J. Cancer, 28: 316–321 (1973).PubMedCrossRefGoogle Scholar
  18. 18.
    A. H. Tashjian, E. F. Voelkel, P. Goldhaber and L. Levine. Successful treatment of hypercalcemía by indomethacin in mice bearing a prostaglandin-producing tumour. Prostaglandins, 3: 515–524 (1973).PubMedGoogle Scholar
  19. 19.
    E. F. Voelkel, A. H. Tashjian, R. Franklin, E. Wasserman and L. Levine. Hypercalcemia and prostaglandins: The VX2 carcinoma model in the rabbit. Metabolism, 24: 973–986 (1975).PubMedCrossRefGoogle Scholar
  20. 20.
    C. S. B. Galasko and A. Bennett. Relationship of bone destruction in skeletal metastases to osteoclast activation and prostaglandins. Nature, 263: 508–510 (1976).PubMedCrossRefGoogle Scholar
  21. 21.
    C. S. B. Galasko, R. Rawlins and A. Bennett. Timing of indomethacin in the control of prostaglandins, osteoclasts and bone destruction produced by VX2 carcinoma in rabbits. Br. J. Cancer, 40: 360–364 (1979).PubMedCrossRefGoogle Scholar
  22. 22.
    S. J. Kirtland and H. Baum. Prostaglandin El may act as a calcium ionophore. Nature New Biol., 236: 47–49 (1972).PubMedCrossRefGoogle Scholar
  23. 23.
    P. W. Reed. Calcium ionophore activity of prostaglandin endoperoxides and stabilized analogs of PGH2. Fed. Proc., 36: 673 (1977).Google Scholar
  24. 24.
    A. Bennett, D. A. Berstock, B. Raja and I. F. Stamford. Survival time after surgery is inversely related to the amounts of prostaglandins extracted from human breast cancers. Br. J. Pharmac., 66: 451P (1979).Google Scholar
  25. 25.
    H. W. Seyberth, G. V. Segre, J. L. Morgan, B. J. Sweetman, J. T. Potts and J. A. Oates. Prostaglandins as mediators of hypercalcemia associated with certain types of cancer. N. Engl. J. Med., 293: 1278–1283 (1975).PubMedCrossRefGoogle Scholar
  26. 26.
    R. C. Coombes, A. M. Neville, P. K. Bondy and T. J. Powles. Failure of indomethacin to reduce hydroxyproline excretion or hypercalcemia in patients with breast cancer. Prostaglandins, 12: 1027–1035 (1976).PubMedGoogle Scholar
  27. 27.
    V. Eisen and D. I. Walker. Effect of ionising radiation on prostaglandin-like activity in tissues. Br. J. Pharmac., 57: 527–532 (1976).CrossRefGoogle Scholar
  28. 28.
    L. Levine. Chemical carcinogens stimulate canine kidney (MDCK) cells to produce prostaglandins. Nature, 268: 447–448 (1977).PubMedCrossRefGoogle Scholar
  29. 29.
    A. T. Mennie, V. Dalley, L. C. Dinneen and H. O. J. Collier. Treatment of radiation-induced gastrointestinal distress with acetylsalicylate. Lancet, 2: 942–943 (1975).PubMedCrossRefGoogle Scholar
  30. 30.
    N. R. Lynch, M. Castes, M. Astoin and J. C. Salomon. Mechanism of inhibition of tumour growth by aspirin and indomethacin. Br. J. Cancer, 38: 503–512 (1978).PubMedCrossRefGoogle Scholar
  31. 31.
    A. Bennett, J. Houghton, D. J. Leaper and I. F. Stamford. Cancer growth, response to treatment and survival time in mice: beneficial effect of the prostaglandin synthesis inhibitor flurbiprofen. Prostaglandins, 17: 179–191 (1979).PubMedGoogle Scholar
  32. 32.
    H. B. Hewitt, E. R. Blake and A. S. Walder. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br. J. Cancer, 33: 241–259 (1976).PubMedCrossRefGoogle Scholar
  33. 33.
    D. J. Leaper, B. French and A. Bennett. Breast cancer and prostaglandins. A new approach to treatment. Br. J. Surg., 66: 683–686 (1979).PubMedCrossRefGoogle Scholar
  34. 34.
    B. J. Northover. Effect of anti-inflammatory drugs on the binding of calcium to cellular membranes in various human and guinea-pig tissues. Br. J. Pharmac., 48: 496–504 (1973).CrossRefGoogle Scholar
  35. 35.
    G. J. Gasic, T. B. Gasic, N. Galanti, T. Johnson and S. Murphy. Platelet-tumour-cell interactions in mice. The role of platelets in the spread of malignant disease. Int. J. Cancer, 11: 704–718 (1973).PubMedCrossRefGoogle Scholar
  36. 36.
    D. A. Berstock, J. Houghton and A. Bennett. Improved anticancer effect by combining cytotoxic drugs with an inhibitor or prostaglandin synthesis. Cancer Treatment Reviews, 6: (Suppl), 69–71 (1979).PubMedCrossRefGoogle Scholar
  37. 37.
    R. J. Gryglewski, B. Panczenko, R. Korbut, L. Grodzinska and A. Ocetkiewicz. Corticosteroids inhibit prostaglandin release from perfused mesenteric blood vessels of rabbit and from perfused lungs of sensitised guinea-pig. Prostaglandins, 10: 343–355 (1975).PubMedGoogle Scholar
  38. 38.
    G. Ritchie. The direct inhibition of prostaglandin synthetase of human breast cancer tissue by ‘Novaldex’. Reviews on Endocrine-Related Cancer (Suppl Oct. 1978 ), 35–39 (1978).Google Scholar
  39. 39.
    A. Robert. Effect of prostaglandins on gastro-intestinal functions. In: Prostaglandins and Thromboxanes. F. Berti, B. Samuelsson and G. P. Velo, eds., Plenum Press, New York, pp. 287–313 (1977).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1981

Authors and Affiliations

  • Alan Bennett
    • 1
  1. 1.Department of SurgeryKing’s College Hospital Medical SchoolLondonEngland

Personalised recommendations